Pipeline
We’re developing antibody drug conjugates against two novel cancer targets using human antibodies selected from SPARTA methodology.

- ADC1
- ADC2
We’re developing antibody drug conjugates against two novel cancer targets using human antibodies selected from SPARTA methodology.